EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Fulcrum Therapeutics's Enterprise Value is $-94.23 Mil.
Fulcrum Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-63.57 Mil. Therefore, Fulcrum Therapeutics's EV-to-FCF for today is 1.48.
The historical rank and industry rank for Fulcrum Therapeutics's EV-to-FCF or its related term are showing as below:
FULC'
s EV-to-FCF Range Over the Past 10 Years
Min: -31.73 Med: -1.76 Max: 78.55
Current: 1.48
During the past 9 years, the highest EV-to-FCF of Fulcrum Therapeutics was 78.55. The lowest was -31.73. And the median was -1.76.
FULC's EV-to-FCF is ranked better than 75.45% of 330
companies
in the Biotechnology industry
Industry Median: 16.36
vs FULC: 1.48
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Fulcrum Therapeutics's PE Ratio (TTM) for today is calculated as:
Fulcrum Therapeutics's share price for today is $3.49.
Fulcrum Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.150.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Fulcrum Therapeutics EV-to-FCF Related Terms
Fulcrum Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Fulcrum Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Fulcrum Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fulcrum Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fulcrum Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Fulcrum Therapeutics's EV-to-FCF falls into.
Fulcrum Therapeutics's current Enterprise Value is $-94.23 Mil.
Fulcrum Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-63.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fulcrum Therapeutics (FULC) has a EV-to-FCF of 1.48 as of Jul. 10, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Fulcrum Therapeutics and its competitors. According to the industry distribution chart, Fulcrum Therapeutics ranks #81 out of 330 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Fulcrum Therapeutics' EV-to-FCF too high?
Fulcrum Therapeutics' current EV-to-FCF is 1.48. The Biotechnology industry median EV-to-FCF is 16.36. Fulcrum Therapeutics' value of 1.48 is 91% below this industry median. Based on the distribution chart, Fulcrum Therapeutics ranks #81 out of 330 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Fulcrum Therapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Fulcrum Therapeutics' EV-to-FCF compare to OBIO and OTLK?
According to the Biotechnology industry distribution chart, Fulcrum Therapeutics ranks #81 out of 330 companies for EV-to-FCF. This places Fulcrum Therapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 16.36. Fulcrum Therapeutics' value of 1.48 is 91% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.36, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fulcrum Therapeutics's current EV-to-FCF of 1.48 is 91% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Fulcrum Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fulcrum Therapeutics's current EV-to-FCF is 1.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulcrum Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Fulcrum Therapeutics (FULC) is currently considered Possible Value Trap. The stock's GF Value™ is $31.40, compared to a current price of $3.49 — trading 88.9% below its estimated fair value. The current EV-to-FCF is 1.48 and 91% below the Biotechnology industry median of 16.36. Fulcrum Therapeutics' overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Fulcrum Therapeutics (FULC), the current EV-to-FCF is 1.48 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fulcrum Therapeutics (FULC) Overvalued in 2026?
Based on GuruFocus' analysis, Fulcrum Therapeutics stock appears to be undervalued.
The current stock price of $3.49 is trading 88.9% below its estimated GF Value™ of $31.40.
GuruFocus considers Fulcrum Therapeutics to be Possible Value Trap.
Key valuation signals for FULC:
EV-to-FCF: 1.48
GF Value™: $31.40 vs. price of $3.49 (88.9% below fair value)
Industry Position: 91% below the Biotechnology median (#81 of 330)
No single metric tells the full story. See the FULC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
44GF Score
Get the complete analysis for FULC
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FULC has been successfully added to your 
